Medical Membranes Companies

The medical membranes market is projected to reach USD 6.66 billion by 2030 from USD 4.31 billion in 2025, at a CAGR of 9.1% during the forecast period. The medical membranes market is driven by increasing chronic diseases such as diabetes, kidney disease, and CVDs, which have increased the demand for more advanced filtration systems to be used to filter, separate, and purify fluids for use in dialysis, drug delivery, and sterile processing. The increasing use of biopharmaceuticals and the increasing demand for high-purity products have created an increased reliance on membranes to perform the functions of filtration and sterilization. Improved healthcare infrastructure and increased emphasis on high-quality and safe medical products are other important drivers of market growth. Technological advancements are a significant contributor to growth as well. The development of new nanofiber membranes, polymers, and surface modification technologies has provided more efficient products, enhanced resistance to chemicals, and increased biocompatibility. Additionally, new manufacturing methods, such as electrospinning and three-dimensional membrane structuring, are opening new applications for assessing patients, treating injuries, and regenerating tissues. In addition to technological advancements, government efforts to encourage domestic production and innovation have created a supportive environment that has provided more resources for improving healthcare research and growing technological development. In many countries, there are efforts to provide access to dialysis treatment and infection prevention products through education and funding for healthcare research.

The medical membranes market is dominated by key manufacturers, including Asahi Kasei Corporation (Japan), Mann+Hummel (Germany), Sartorius AG (Germany), Merck KGaA (Germany), Solventum (US), Cytiva (US), W. L. Gore & Associates, Inc.  (US), Kovalus Separation Solutions (US), and Cobetter (China), among others. These players have adopted product launches, deals, and expansions from January 2023 to July 2025 to expand their market share and geographical reach. In September 2025, Solventum entered into an agreement to sell its Purification & Filtration business to Thermo Fisher Scientific, marking a major step in its ongoing transformation plan. The development shifted the ownership of key filtration and medical-membrane technologies to Thermo Fisher, positioning both companies for focused growth in their respective portfolios.

To know about the assumptions considered for the study download the pdf brochure

Asahi Kasei Corporation (Japan) is a leading chemical and material provider for various end-use industries, such as construction, food & beverage, and pharmaceutical. The company operates through three business segments—material, homes, and health care. Medical membrane products are offered under the health care segment. The company has developed a complete filtration module, named Microza, that uses the hollow fiber membranes developed by Asahi Kasei Chemicals. Microza has a developed track record for high performance in a wide variety of applications such as electronics, water & wastewater filtration, food, pharmaceutical, municipal water, energy, and environmental. Microza uses several types of hollow fiber membranes, microfiltration & ultrafiltration membranes, and various organic polymers, such as polysulfone, PE, and PVDF. The company offers its medical membranes products through Asahi Kasei Medical Co., Ltd., and has other brands as well in the membrane field category, such as ViE and APS. It holds a high market share in areas such as hemodialysis, therapeutic apheresis, transfusion therapy, and virus removal for biotherapeutic products. It continues to grow as a pioneer in blood-related medical fields. The company operates in Asia/Oceania, Europe, the Americas, and Japan. Asahi Kasei has a global presence, with 309 subsidiaries in approximately 40 countries. The company also has two membrane manufacturing facilities in Asia Pacific. In 2024, the company had an expenditure of USD 735.1 million in research and development.

Sartorius AG (Germany) is a leading supplier of pharmaceutical and laboratory equipment. The company operates its bioprocess business as a legally independent subgroup under Sartorius Stedim Biotech S.A. As of December 31, 2024, Sartorius AG owned 71.5% of Sartorius Stedim Biotech S.A. The company operates through two divisions, namely, Bioprocess Solutions and Lab Products & Services. It provides medical membrane products under its bioprocess solutions segment. The company offers medical membranes under the brand name Unisart. As a leading global player, Sartorius maintains a presence in over 110 countries through its own manufacturing sites, sales offices, and local representatives. It has geographic presence in the Americas, Asia Pacific, Europe, and the Middle East & Africa. In 2024, Sartorius invested USD 213 million in research and development (R&D).

 Related Reports:

Medical Membranes Market by Material (PSU, PES, PVDF, PTFE, PP, PAN, PA, Modified Acrylics), Process Technology (Ultrafiltration, Microfiltration, Nanofiltration), Application (Pharmaceutical Filtration, Hemodialysis, IV Fusion & Sterile Filtration, Membrane Oxygenator), and Region - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com